Kim Drapkin is a financial advisor at DeuteRx. Kim has also served as a board member and chair of audit committee at Proteostasis Therapeutics, Inc. from February 2019 to December 2020. Prior to that, they were the principal and founder of KCD Financial Consultants LLC from August 2009 to August 2015. During their time at the company, they served as interim CFO at a number of biotechnology start-ups including Avila Therpeutics, Inc., Blueprint Medicines Corporation, Deuterx LLC, Eleven Biotherapeutics, Inc., Jounce Therapeutics, Inc., NinePoint Medical, Inc., Permeon Biologics, Inc., Voyager Therapeutics, Inc. and Warp Drive Bio LLC. Before that, they served as the chief financial officer of EPIX Pharmaceuticals from January 2005 to August 2009 and as director of finance at Millennium Pharmaceuticals from January 1995 to December 2005.
Kim Drapkin has a Bachelor’s Degree in Accounting from Babson College and has completed Harvard Business School Executive Education courses in both Women on Boards and Women's Leadership Forum.